Celer Diagnostics is a biotechnology company based in Canada that specializes in non-invasive cancer diagnostics through liquid biopsy solutions. Founded by Dr. Faezeh Shekari, the company focuses on early cancer detection using extracellular vesicle (EV)-based biomarkers. Their technology requires only a small blood sample and delivers results within two hours, targeting early-stage cancers, including breast cancer.

The company offers Celer Kits, which are designed to detect and predict breast cancer by analyzing multiple biomarkers. Their liquid biopsy approach utilizes biofluids to identify circulating tumor cells and other disease-specific markers, providing a cost-effective and efficient alternative to traditional biopsies. Celer’s innovative methodology emphasizes the use of extracellular vesicles as natural biomarkers, supporting early diagnosis and ongoing monitoring.

Led by Dr. Shekari, who has extensive expertise in EV biology, Celer Diagnostics is committed to advancing diagnostic accuracy and accessibility. The company aims to expand its offerings to include other cancer types, focusing on precision medicine and improving patient outcomes.